Miromatrix Medical Q2 EPS $(0.24) Beats $(0.32) Estimate, Sales $8.52K Miss $10.00K Estimate
Portfolio Pulse from vinayak@benzinga.com
Miromatrix Medical (NASDAQ:MIRO) reported Q2 losses of $(0.24) per share, beating the analyst consensus estimate of $(0.32) by 25 percent. This is a 40 percent improvement over the same period last year. However, the company's quarterly sales of $8.52 thousand missed the analyst consensus estimate of $10.00 thousand by 14.83 percent, despite a 115.51 percent increase over last year.
August 14, 2023 | 8:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Miromatrix Medical's Q2 results showed mixed performance with EPS beating estimates but sales missing them. The EPS improvement could be seen positively, but the sales miss might concern investors.
Miromatrix Medical's EPS beat estimates, which is a positive signal for investors as it indicates better-than-expected profitability. However, the company's sales missed estimates, which could be a concern as it might indicate weaker-than-expected demand or operational issues. The net impact on the stock price could be neutral in the short term as the positive and negative factors balance each other out.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100